Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month
View Press Release Bordentown, NJ – March 1, 2021 – Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today announced its collaboration with and support of the amyloidosis advocacy community as Amyloidosis Awareness Month begins. The campaign was created to spread awareness about this rare disease and its symptoms to help prompt earlier diagnosis for patients. In honor of the month and